Table 1 Characteristics that were used the analysis: all patients (Entire cohort) and split by training and testing datasets^a

n

30,961

23,275

7686

Sex (male)

n (%)

16,885 (54.54)

12,723 (54.66)

4163 (54.15)

BMI

<  18.5

1305 (4.21)

978 (4.2)

327 (4.25)

≥ 18.5, <  25

9926 (32.06)

7461 (32.06)

2465 (32.07)

≥ 25, <  30

10,358 (33.45)

7758 (33.33)

2600 (33.83)

≥ 30

9372 (30.27)

7078 (30.41)

2294 (29.85)

CRS

n (%)

590 (1.91)

445 (1.91)

145 (1.89)

Anxiety

n (%)

3123 (10.09)

2375 (10.2)

748 (9.73)

Atopy

n (%)

3809 (12.3)

2868 (12.32)

941 (12.24)

Depression

n (%)

3413 (11.02)

2605 (11.19)

808 (10.51)

Diabetes

n (%)

5001 (16.15)

3789 (16.28)

1212 (15.77)

Eosinophils > 2%

n (%)

20,363 (65.77)

15,299 (65.73)

5064 (65.89)

GERD

2759 (8.91)

2108 (9.06)

651 (8.47)

GOLD

1

8077 (26.09)

6017 (25.85)

2060 (26.8)

2

15,536 (50.18)

11,749 (50.48)

3787 (49.27)

3

6322 (20.42)

4730 (20.32)

1592 (20.71)

4

1026 (3.31)

779 (3.35)

247 (3.21)

Heart failure

n (%)

4685 (15.13)

3579 (15.38)

1106 (14.39)

Hypertension

n (%)

10,515 (33.96)

7906 (33.97)

2609 (33.94)

IHD

n (%)

7134 (23.04)

5379 (23.11)

1755 (22.83)

Smoking

ex

14,447 (46.66)

10,920 (46.92)

3527 (45.89)

current

16,514 (53.34)

12,355 (53.08)

4159 (54.11)

Therapy type

none

11,621 (37.53)

8775 (37.7)

2846 (37.03)

mono

4071 (13.15)

3018 (12.97)

1053 (13.7)

dual

10,261 (33.14)

7722 (33.18)

2539 (33.03)

triple

5008 (16.18)

3760 (16.15)

1248 (16.24)